1. Aspirin and Cardioprevention in 2018

2. 3 Settings for Initiating Aspirin

3. Serious Vascular Events in Primary Prevention Trials

4. USPSTF Analysis

5. USPSTF 2016 Statement of Aspirin Use

6. Contemporary Clinical Trials Exploring the Role of Aspirin for Cardioprevention

7. Patient Case 1

8. When to Consider Aspirin?

9. Aspirin for Secondary Prevention

10. Patient Case 2

11. Approach to Considering Aspirin Use for Primary Prevention

12. Patient Case 2

13. ARRIVE Study Design

14. ARRIVE Baseline Characteristics

15. ARRIVE Results

16. ARRIVE: Components of Primary Endpoint Cumulative Incidence

17. ARRIVE Results

18. ARRIVE Interpreting the Results

19. Primary Prevention Trials With Aspirin in Patients With Diabetes

20. ASCEND Study Design

21. ASCEND Aspirin Effect on Vascular and Bleeding Outcomes

22. Aspirin Recommendations for Patients With Diabetes

23. ASPREE Study Design

24. ASPREE Results

25. ASPREE Results (cont)

26. Vascular Events Avoided vs Major Bleeds

27. Risk Factors for GI Bleeding with Aspirin

28. Conclusion

29. Abbreviations

30. Abbreviations (cont)